Could targeting only the main prostate tumor reduce radiation side effects?

NCT ID NCT07574489

Not yet recruiting Symptom relief Sponsor: University of Nebraska Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This study compares two types of radiation therapy for prostate cancer: one that boosts the whole prostate gland and one that boosts only the main tumor. About 186 men will be randomly assigned to one of the two treatments. The goal is to see which approach causes fewer urinary and bowel side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiation therapy (stereotactic body radiotherapy, SBRT)
What this could lead to: If it works, this could lead to fewer urinary and bowel side effects for men receiving radiation for prostate cancer.
What could go wrong: This is an early-phase trial with only 186 participants, so results may not apply to everyone. There is also a risk that focusing on the main tumor might miss other cancer cells.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE ADENOCARCINOMA PROSTATE CANCER

Contacts and locations

Locations

Fred & Pamela Buffet Cancer Center

Omaha, Nebraska, 68198, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.